FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:190-192 July 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bone, H. G. PubMed Citation

To the Editor: In their report on 10 years of alendronate therapy for osteoporosis in postmenopausal women, Bone et al. (March 18 issue)¹ mention the long retention time of alendronate in bone as an advantage. This view is based on the fact that the large reduction in bone turnover is present five years after the discontinuation of treatment. The authors claim that histomorphometric analysis confirmed long-term bone safety,^2,3 but the study they cite followed treatment for only two to three years in a small group of patients receiving 20 mg of alendronate.² What the present study actually shows is that . . . [Full Text of this Article]

This article has been cited by other articles:

• Epstein, J.B., Elad, S., Eliav, E., Jurevic, R., Benoliel, R. (2007). Orofacial Pain in Cancer: Part II--Clinical Perspectives and Management. FAKE JDR 86: 506-518 [Abstract] [Full Text]  
• Badros, A., Weikel, D., Salama, A., Goloubeva, O., Schneider, A., Rapoport, A., Fenton, R., Gahres, N., Sausville, E., Ord, R., Meiller, T. (2006). Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. JCO 24: 945-952 [Abstract] [Full Text]